Yong Wang  MBA    Chairman


Yong Wang is the Chairman of HebeCell Corp. and Vice Chairman of VcanBio Cell& Gene Engineering Co., Ltd.(Parent Company).  Mr. Wang also serves as the Chairman and Chief Executive Officer of several VcanBio subsidiaries in China, including Union Stem Cell&Gene Engineering Co., Ltd., Beijing VcanBio Investment Corp., Shanghai HeZeTongJi Biotech Co., Ltd. From 2012 to 2014, he was the Chairman of the Board of Alliancells Bioscience Co., Ltd., a pioneer company in China developing clinical drug, stem cell anti-aging product, and stem cell cosmetic product. Prior to that, he served as the General Manager of Hongkan Investment Co., Ltd. Mr. Wang earned an MBA degree at Nankai University in China.

Shi-Jiang (John) Lu Ph.D., MPH    President & CEO

CAN_9724sShi-Jiang (John) Lu is currently the President and CEO of VcanBio CTB. and HebeCell Corporation. Before joining HebeCell, John was the Senior Director of Research at Ocata Therapeutics, which was recently acquired by Astellas, the 2nd largest pharmaceutical company of Japan. John is an expert in stem cell biology and regenerative medicine with 20 years of experiences. John has been conducting translational researches and novel therapeutic strategies utilizing human embryonic stem cells (hESC), induced pluripotent stem cells (iPSC) and their derivatives. The goal of his research is to generate hESC/iPSC-derived products for the treatment of human diseases. He has extensive experience in process development and large-scale production of human pluripotent stem cell derivatives for clinical applications.


John received his Ph.D. degree in Oncology and Cancer Biology from University of Toronto/Ontario Cancer Institute, an M.P.H degree from Columbia University, an M.S. degree in Oncology from Peking Union Medical College and a B.S. degree in Biochemistry from Wuhan University.



Allen Feng Ph.D.    Chief Scientific Officer

CAN_9798sDr. Allen Feng is the Chief Scientific Officer of the HebeCell Corp. Prior to joining HebeCell, he was the Director of Cell Biology of Semma Therapeutics, where Dr. Feng played a key role in the successful establishment of the process development operation. Prior to Semma, Dr. Feng worked as R&D Head of Stem Cell Bioprocessing Group at EMD Millipore (a US subsidiary of Merck, KGaA). Before joining Millipore, Dr. Feng was Director and Senior Scientist at Advanced Cell Technology (later became Ocata Therapeutics and Astellas). At Advanced Cell Technology, Dr. Feng was the major contributor and inventor of several key discoveries such as the patented Hemangioblast technology (published in Nature Methods); generation of donorless red blood cells (published in Blood); and generation of HLA-negative functional platelets from human pluripotent stem cells (published in Stem Cell Reports).


Dr. Feng graduated with a Ph.D. and an M.S. degree from Institute of Zoology at Chinese Academy of Sciences. He earned his B.S. degree from Beijing Normal University. He was the Associate Professor and the Deputy Director of the State Key Laboratory of Reproductive Biology in Chinese Academy of Sciences. Dr. Feng received the prestigious award of Wu Jie-ping Medical Research Award and the Paul Janssen Pharmaceutical Research Award in 1995, as well as the Fellowship of Marie-Curie of the European Union and the Wellcome Trust (U.K).